Gilead Sciences Stocks List

Recent Signals

Date Stock Signal Type
2021-04-14 GILD Crossed Above 20 DMA Bullish
2021-04-14 GILD Crossed Above 200 DMA Bullish
2021-04-14 GILD Bollinger Band Squeeze Range Contraction
2021-04-14 HGEN Stochastic Reached Oversold Weakness
2021-04-14 HGEN Narrow Range Bar Range Contraction
2021-04-14 HGEN Spinning Top Other
2021-04-14 HOOK Crossed Above 50 DMA Bullish
2021-04-14 NRIX 20 DMA Resistance Bearish
2021-04-14 NRIX Pocket Pivot Bullish Swing Setup

Recent News for Gilead Sciences Stocks

Date Stock Title
Apr 14 GILD Vaccine transparency is ‘the best course of action’: Doctor 
Apr 14 GILD U.S. in unique position to force increased accountability at the WHO: FDD
Apr 14 NRIX Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
Apr 14 GILD Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer
Apr 14 GILD Gilead’s Bladder Cancer Drug Trodelvy Gets FDA Nod
Apr 14 HOOK HOOKIPA Pharma to Present at Kempen Life Science Conference
Apr 14 GILD A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus
Apr 13 GILD U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Apr 13 NRIX Nurix Therapeutics EPS misses by $0.20, misses on revenue
Apr 13 NRIX Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Apr 13 GILD Gilead wins FDA accelerated approval for Trodelvy in urothelial cancer
Apr 13 GILD How COVID-19 transformed the biotech industry
Apr 13 GILD Gilead halts remdesivir trial in high-risk COVID-19 patients
Apr 10 HOOK HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
Apr 9 GILD Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor
Apr 9 HGEN Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study
Apr 9 HGEN Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Apr 9 HGEN Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?
Apr 9 HGEN Humanigen to present positive Phase 1 data for brain cancer therapy at AACR meeting
Apr 8 GILD Biotech Stocks Could Use A Win — Will The First Quarter Offer That?

Gilead Sciences, Inc. , is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

More about Gilead Sciences
Browse All Tags